Company: INMB
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001213900-25-104141
Chunk: 7

Company: Inmune Bio, Inc.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 1
Chunk 7
---
 
  
    CASH AND CASH EQUIVALENTS AT END OF PERIOD 
    $27,734  
    $33,552 

    SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION: 

    Cash paid for income taxes 
    $-  
    $- 
  
    Cash paid for interest expense 
    $-  
    $661 

    SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: 

    Right of use assets obtained in exchange for lease obligations 
    $702  
    $- 

The accompanying notes are an integral part of
these unaudited condensed consolidated financial statements.

5

INMUNE BIO INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS

NOTE 1 – ORGANIZATION AND DESCRIPTION
OF BUSINESS

INmune Bio Inc. (the “Company” or “INmune Bio”)
was organized in the State of Nevada on September 25, 2015 and is a clinical stage biotechnology pharmaceutical company focused on developing
and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing
to disease. INmune Bio has three product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively
neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases and was used for its Alzheimer’s
clinical trial (“XPro”). The CORDStrom product platform is a pooled, human umbilical cord mesenchymal stem cell product currently
being developed to treat recessive dystrophic epidermolysis bullosa (“RDEB”). The Natural Killer Cell Priming Platform includes
INKmune aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s
product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors
and chronic inflammation.

NOTE 2 – GOING CONCERN 

These unaudited condensed consolidated financial
statements have been prepared in accordance with generally accepted accounting principles applicable to a going concern, which contemplates
the realization of assets and the satisfaction of liabilities in the normal course of business.

The Company has incurred significant losses and
negative cash flows from operations since inception and expects to incur additional losses until such time that it can generate